Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MediciNova Inc. | MN-166 (ibudilast) | Alcohol Use Disorder (AUD) | Phase 2b | Data Released | Oral | Psychiatric |
| MediciNova Inc. | Ibudilast (MN-166) | Chemotherapy-induced peripheral neuropathy (CIPN) | Phase 2b | Oral | Neurology | |
| MediciNova Inc. | Ibudilast (MN-166) | Progressive multiple sclerosis (progressive MS) | Phase 2b | Oral | Neurology | |
| MediciNova Inc. | MN-001 (Tipelukast) - (NATG-202) | Non-alcoholic fatty liver disease (NAFLD) with Type 2 Diabetes Mellitus and Hypertriglyceridemia | Phase 2 | Ongoing | Oral | Endocrinology |
| MediciNova Inc. | MN-166 (ibudilast) - (OXTOX) | Metastatic colorectal cancer | Phase 2 | Enrollment Conclusion | Oral | Oncology |
| MediciNova Inc. | Ibudilast - (MN-166) | COVID-19 / acute respiratory distress syndrome (ARDS) | Phase 2 | Oral | COVID-19 | |
| MediciNova Inc. | MN-001 | Idiopathic pulmonary fibrosis (IPF) | Phase 2 | oral | Respiratory | |
| MediciNova Inc. | Ibudilast (MN-166) | Glioblastoma | Phase 2 | Data Released | Oral | Oncology |
